ECL Ecolab Inc.

Ecolab Acquires Gallay Medical & Scientific

Ecolab Inc., the global leader in water, hygiene and energy technologies and services that protect people and vital resources, has acquired , a leading distributor of endoscopy, central sterile department, dental and pharmaceutical solutions in Australia and New Zealand. Headquartered in Melbourne the company’s sales for the fiscal year ending June 30, 2019, were approximately AU$42 million (US$28 million).

“Ecolab is committed to providing hospitals and healthcare facilities throughout the world with innovative infection prevention solutions for patients and healthcare providers,” said Gergely Sved, senior vice president and general manager of Ecolab Healthcare. “Gallay Medical & Scientific, founded and operated by the Vat family, is a well-respected distributor of medical solutions that shares our focus on technical and service excellence, and will enable us to meet the needs of our growing customer base in Australia and New Zealand.”

Gallay Medical & Scientific is a leader in providing medical devices, equipment, chemistry and service to the medical, dental, scientific and pharmaceutical industries. Founded by Jan Vat in 1965, the company has approximately 100 employees, including its field service team, and operates a research, development and technical centre in Melbourne with offices, workshops and warehouses throughout Australia and New Zealand.

Ecolab Healthcare serves more than 8,700 hospitals and health systems in more than 90 countries, delivering solutions that help ensure cleaner, safer and healthier environments for patients and healthcare providers. Its unique program delivery model brings together cutting-edge technology, real-time information, personally delivered service and best-practice training for improved outcomes, operational efficiencies and increased patient satisfaction.

About Ecolab

A trusted partner at nearly three million customer locations, Ecolab (ECL) is the global leader in water, hygiene and energy technologies and services that protect people and vital resources. With annual sales of $15 billion and 49,000 associates, Ecolab delivers comprehensive solutions, data-driven insights and on-site service to promote safe food, maintain clean environments, optimise water and energy use, and improve operational efficiencies for customers in the food, healthcare, energy, hospitality and industrial markets in more than 170 countries around the world. .

Ecolab has more than 1,200 associates throughout Australia and New Zealand.

Follow us on Twitter , Facebook at , LinkedIn at or Instagram at .

EN
02/10/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ecolab Inc.

Ecolab Inc.: Update to credit profile – Focus on faster growth

Our credit view of this issuer reflects is strong earnings growth, constrained by event risk related to acquisitions.

Ecolab Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's Ratings assigns A3 rating to Ecolab's new senior unsecured not...

Moody's Ratings (Moody's) assigned an A3 rating to Ecolab Inc.'s (Ecolab) new $500 million senior unsecured notes due in 2035. The net proceeds of the notes issuance will be used for general corporate purposes, including partial funding of the Ovivo Electronics acquisition and repayment of indebtedn...

Ecolab Inc: 4 directors

Four Directors at Ecolab Inc sold after exercising options/bought/sold 9,625 shares at between 263.050USD and 264.692USD. The significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all...

Ecolab Inc.: Update to credit profile – Focus on faster growth

Our credit view of this issuer reflects its conservative leverage targets and excellent liquidity, constrained by its ongoing efforts to improve lower margin healthcare business.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch